164 related articles for article (PubMed ID: 36824562)
1. Perspectives on and Quality of Life in Skin of Color Patients With Mycosis Fungoides/Sézary Syndrome: A Qualitative Analysis.
Abraham J; Wei G; Desai SR; Chen PL; Seminario-Vidal L
Cureus; 2023 Jan; 15(1):e34054. PubMed ID: 36824562
[TBL] [Abstract][Full Text] [Related]
2. Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.
Molloy K; Jonak C; Woei-A-Jin FJSH; Guenova E; Busschots AM; Bervoets A; Hauben E; Knobler R; Porkert S; Fassnacht C; Cowan R; Papadavid E; Beylot-Barry M; Berti E; Alberti Violetti S; Estrach T; Matin R; Akilov O; Vakeva L; Prince M; Bates A; Bayne M; Wachsmuch R; Wehkamp U; Marschalko M; Servitje O; Turner D; Weatherhead S; Wobser M; Sanches JA; McKay P; Klemke D; Peng C; Howles A; Yoo J; Evison F; Scarisbrick J
Br J Dermatol; 2020 Mar; 182(3):770-779. PubMed ID: 31049926
[TBL] [Abstract][Full Text] [Related]
3. Measurement of Quality of Life in Patients with Mycosis Fungoides/Sézary Syndrome Cutaneous T-Cell Lymphoma: Development of an Electronic Instrument.
McCaffrey S; Black RA; Nagao M; Sepassi M; Sharma G; Thornton S; Kim YH; Braverman J
J Med Internet Res; 2019 Jan; 21(1):e11302. PubMed ID: 30617041
[TBL] [Abstract][Full Text] [Related]
4. Extracorporeal photophoresis: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
[TBL] [Abstract][Full Text] [Related]
5. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
6. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
7. Mycosis fungoides and Sézary syndrome.
Jonak C; Tittes J; Brunner PM; Guenova E
J Dtsch Dermatol Ges; 2021 Sep; 19(9):1307-1334. PubMed ID: 34541796
[TBL] [Abstract][Full Text] [Related]
8. Morphology of Mycosis Fungoides and Sézary Syndrome in Skin of Color.
Espinosa ML; Walker CJ; Guitart J; Mhlaba JM
Cutis; 2022 Mar; 109(3):E3-E7. PubMed ID: 35659141
[TBL] [Abstract][Full Text] [Related]
9. Clinical severity measures and quality-of-life burden in patients with mycosis fungoides and Sézary syndrome: comparison of generic and dermatology-specific instruments.
Herbosa CM; Semenov YR; Rosenberg AR; Mehta-Shah N; Musiek AC
J Eur Acad Dermatol Venereol; 2020 May; 34(5):995-1003. PubMed ID: 31630443
[TBL] [Abstract][Full Text] [Related]
10. Mycosis fungoides and Sézary syndrome: a population-wide study on prevalence and health care use in Finland in 1998-2016.
Keto J; Hahtola S; Linna M; Väkevä L
BMC Health Serv Res; 2021 Feb; 21(1):166. PubMed ID: 33618714
[TBL] [Abstract][Full Text] [Related]
11. Quality of life in patients with Mycosis Fungoides and Sézary Syndrome: a systematic review of the literature.
Ottevanger R; van Beugen S; Evers AWM; Willemze R; Vermeer MH; Quint KD
J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):2377-2387. PubMed ID: 34331819
[TBL] [Abstract][Full Text] [Related]
12. Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sézary Syndrome.
Hirotsu KE; Neal TM; Khodadoust MS; Wang JY; Rieger KE; Strelo J; Hong E; Kim YH; Kwong BY
JAMA Dermatol; 2021 Jun; 157(6):700-707. PubMed ID: 33881447
[TBL] [Abstract][Full Text] [Related]
13. Itch in patients with cutaneous T-cell lymphoma as a quality of life indicator.
Ottevanger R; van Beugen S; Evers AWM; Willemze R; Vermeer MH; Quint KD
JAAD Int; 2022 Dec; 9():57-64. PubMed ID: 36147217
[TBL] [Abstract][Full Text] [Related]
14. Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/Sézary syndrome than quantification of CD26- or CD7- CD4+ T-cells.
Lyapichev KA; Bah I; Huen A; Duvic M; Routbort MJ; Wang W; Jorgensen JL; Medeiros LJ; Vega F; Craig FE; Wang SA
Cytometry B Clin Cytom; 2021 Mar; 100(2):183-191. PubMed ID: 32667737
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and severity of pruritus in cutaneous T cell lymphoma.
Vij A; Duvic M
Int J Dermatol; 2012 Aug; 51(8):930-4. PubMed ID: 22788808
[TBL] [Abstract][Full Text] [Related]
16. Immune evasion and current immunotherapy strategies in mycosis fungoides (MF) and Sézary syndrome (SS).
Shalabi D; Bistline A; Alpdogan O; Kartan S; Mishra A; Porcu P; Nikbakht N
Chin Clin Oncol; 2019 Feb; 8(1):11. PubMed ID: 30691274
[TBL] [Abstract][Full Text] [Related]
17. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome.
Trautinger F; Knobler R; Willemze R; Peris K; Stadler R; Laroche L; D'Incan M; Ranki A; Pimpinelli N; Ortiz-Romero P; Dummer R; Estrach T; Whittaker S
Eur J Cancer; 2006 May; 42(8):1014-30. PubMed ID: 16574401
[TBL] [Abstract][Full Text] [Related]
18. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
[TBL] [Abstract][Full Text] [Related]
19. Detection of clonal T-cell receptor gamma gene rearrangements in early mycosis fungoides/Sezary syndrome by polymerase chain reaction and denaturing gradient gel electrophoresis (PCR/DGGE).
Wood GS; Tung RM; Haeffner AC; Crooks CF; Liao S; Orozco R; Veelken H; Kadin ME; Koh H; Heald P
J Invest Dermatol; 1994 Jul; 103(1):34-41. PubMed ID: 8027579
[TBL] [Abstract][Full Text] [Related]
20. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.
Olsen EA; Whittaker S; Kim YH; Duvic M; Prince HM; Lessin SR; Wood GS; Willemze R; Demierre MF; Pimpinelli N; Bernengo MG; Ortiz-Romero PL; Bagot M; Estrach T; Guitart J; Knobler R; Sanches JA; Iwatsuki K; Sugaya M; Dummer R; Pittelkow M; Hoppe R; Parker S; Geskin L; Pinter-Brown L; Girardi M; Burg G; Ranki A; Vermeer M; Horwitz S; Heald P; Rosen S; Cerroni L; Dreno B; Vonderheid EC; ; ;
J Clin Oncol; 2011 Jun; 29(18):2598-607. PubMed ID: 21576639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
